Partnerships
GlaxoSmithKline Immuno-Oncology Financial Collaboration
Our immuno-oncology financial collaboration with GlaxoSmithKline (GSK) is focused upon the development and commercialization of Anaptys-generated checkpoint antagonist antibodies to PD-1 and TIM-3. The exclusively licensed products being advanced by GSK under this partnership include Jemperli™ (dostarlimab) and cobolimab in second line NSCLC.
Significant potential royalties from GSK immuno-oncology financial collaboration
Royalties
(Anti-PD-1 antagonist)
8% royalties on annual net sales <$1B**
- 12-25% royalties on annual net sales ≥ $1B
Cobolimab(Anti-TIM-3 antagonist)
- show in combination with Jemperli
- 4-8% royalties on annual net sales (Cobolimab portion)
- 8-25% royalties on annual net sales (Jemperli portion)
Remaining Milestones
(Anti-PD-1 antagonist)
$15mm regulatory
$15mm regulatory
$90MM commercial on annual net sales <$1B**
- $75mm commercial on annual net sales ≥ $1B
Cobolimab(Anti-TIM-3 antagonist)
- $5MM clinical development
- $90MM regulatory
- $165MM commercial
- $250mm Jemperli Capped Non-Recourse Monetization
- 2021 transaction in exchange for selected** Jemperli receivables until Sagard paid back one of the following capped returns:
- $312.5MM (125%) by end 2026, or
- $337.5MM (135%) by end 2027, or
- $412.5MM (165%) if after 2027
To access scientific publications on this topic, please click here.